Changes in insulin and insulin signaling in Alzheimer's disease: Cause or consequence?

Journal of Experimental Medicine

Volumn 213, Issue 8, 2016, Pages 1375-1385

  Stanley, Molly ^a   Macauley, Shannon L ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; INSULIN; OLIGOMER; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DIABETIC PATIENT; DISEASE EXACERBATION; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84983002115     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20160493     Document Type: Article

References (84)

1. Allen, K.V., B.M. Frier, and M.W. Strachan. 2004. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur. J. Pharmacol. 490:169-175. http://dx.doi.org/10.1016/j.ejphar.2004.02.054
2. Baker, L.D., D.J. Cross, S. Minoshima, D. Belongia, G.S. Watson, and S. Craft. 2011. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch. Neurol. 68:51-57. http://dx.doi.org/10.1001/archneurol.2010.225
3. Banks, W.A. 2004. The source of cerebral insulin. Eur. J. Pharmacol. 490:5-12. http://dx.doi.org/10.1016/j.ejphar.2004.02.040
4. Banks, W.A., J.B. Jaspan, and A.J. Kastin. 1997. Selective, physiological transport of insulin across the blood-brain barrier: novel demonstration by species-specific radioimmunoassays. Peptides. 18:1257-1262. http://dx.doi.org/10.1016/S0196-9781(97)00198-8
5. Becker, K., S. Freude, J. Zemva, O. Stöhr, W. Krone, and M. Schubert. 2012. Chronic peripheral hyperinsulinemia has no substantial influence on tau phosphorylation in vivo. Neurosci. Lett. 516:306-310. http://dx.doi.org/10.1016/j.neulet.2012.04.022
6. Biessels, G.J., and Y.D. Reijmer. 2014. Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes. 63:2244-2252. http://dx.doi.org/10.2337/db14-0348
7. Bomfim, T.R., L. Forny-Germano, L.B. Sathler, J. Brito-Moreira, J.C. Houzel, H. Decker, M.A. Silverman, H. Kazi, H.M. Melo, P.L. McClean, et al. 2012. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers. J. Clin. Invest. 122:1339-1353. http://dx.doi.org/10.1172/JCI57256
8. Brief, D.J., and J.D. Davis. 1984. Reduction of food intake and body weight by chronic intraventricular insulin infusion. Brain Res. Bull. 12:571-575. http://dx.doi.org/10.1016/0361-9230(84)90174-6
9. Bucht, G., R. Adolfsson, F. Lithner, and B. Winblad. 1983. Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med. Scand. 213:387-392. http://dx.doi.org/10.1111/j.0954-6820.1983.tb03756.x
10. Chao, A.C., T.C. Lee, S.H. Juo, and D.I. Yang. 2016. Hyperglycemia Increases the Production of Amyloid β-peptide leading to decreased endothelial tight junction. CNS Neurosci. Ther. 22:291-297. http://dx.doi.org/10.1111/cns.12503
11. Chen, Y., Y. Zhao, C.L. Dai, Z. Liang, X. Run, K. Iqbal, F. Liu, and C.X. Gong. 2014. Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice. Exp. Neurol. 261:610-619. http://dx.doi.org/10.1016/j.expneurol.2014.06.004
12. Chua, L.M., M.L. Lim, P.R. Chong, Z.P. Hu, N.S. Cheung, and B.S. Wong. 2012. Impaired neuronal insulin signaling precedes Aβ42 accumulation in female AβPPsw/PS1ΔE9 mice. J. Alzheimers Dis. 29:783-791.
13. Claxton, A., L.D. Baker, C.W. Wilkinson, E.H. Trittschuh, D. Chapman, G.S. Watson, B. Cholerton, S.R. Plymate, M. Arbuckle, and S. Craft. 2013. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. J. Alzheimers Dis. 35:789-797. http://dx.doi.org/10.3233/JAD-122308
14. Claxton, A., L.D. Baker, A. Hanson, E.H. Trittschuh, B. Cholerton, A. Morgan, M. Callaghan, M. Arbuckle, C. Behl, and S. Craft. 2015. Long acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J. Alzheimers Dis. 45:1269-1270. http://dx.doi.org/10.3233/JAD-15900
15. Craft, S., J. Newcomer, S. Kanne, S. Dagogo-Jack, P. Cryer, Y. Sheline, J. Luby, A. Dagogo-Jack, and A. Alderson. 1996. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol. Aging. 17:123-130.
16. Craft, S., E. Peskind, M.W. Schwartz, G.D. Schellenberg, M. Raskind, and D. Porte Jr. 1998. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 50:164-168. http://dx.doi.org/10.1212/WNL.50.1.164
17. Craft, S., S. Asthana, J.W. Newcomer, C.W. Wilkinson, I.T. Matos, L.D. Baker, M. Cherrier, C. Lofgreen, S. Latendresse, A. Petrova, et al. 1999. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry. 56:1135-1140. http://dx.doi.org/10.1001/archpsyc.56.12.1135
18. Craft, S., S. Asthana, G. Schellenberg, L. Baker, M. Cherrier, A.A. Boyt, R.N. Martins, M. Raskind, E. Peskind, and S. Plymate. 2000. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann. N. Y. Acad. Sci. 903:222-228. http://dx.doi.org/10.1111/j.1749-6632.2000.tb06371.x
19. Craft, S., S. Asthana, D.G. Cook, L.D. Baker, M. Cherrier, K. Purganan, C. Wait, A. Petrova, S. Latendresse, G.S. Watson, et al. 2003. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology. 28:809-822. http://dx.doi.org/10.1016/S0306-4530(02)00087-2
20. Craft, S., L.D. Baker, T.J. Montine, S. Minoshima, G.S. Watson, A. Claxton, M. Arbuckle, M. Callaghan, E. Tsai, S.R. Plymate, et al. 2012. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69:29-38. http://dx.doi.org/10.1001/archneurol.2011.233
21. Dankner, R., A. Chetrit, M.H. Shanik, I. Raz, and J. Roth. 2009. Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care. 32:1464-1466. http://dx.doi.org/10.2337/dc09-0153
22. De Felice, F.G., M.N. Vieira, T.R. Bomfim, H. Decker, P.T. Velasco, M.P. Lambert, K.L. Viola, W.Q. Zhao, S.T. Ferreira, and W.L. Klein. 2009. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc. Natl. Acad. Sci. USA. 106:1971-1976. http://dx.doi.org/10.1073/pnas.0809158106
23. Dimitriadis, G., P. Mitrou, V. Lambadiari, E. Maratou, and S.A. Raptis. 2011. Insulin effects in muscle and adipose tissue. Diabetes Res. Clin. Pract. 93:S52-S59. http://dx.doi.org/10.1016/S0168-8227(11)70014-6
24. Draznin, B. 2006. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 55:2392-2397. http://dx.doi.org/10.2337/db06-0391
25. Fernandez, A.M., and I. Torres-Alemán. 2012. The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 13:225-239. http://dx.doi.org/10.1038/nrn3209
26. Fishel, M.A., G.S. Watson, T.J. Montine, Q. Wang, P.S. Green, J.J. Kulstad, D.G. Cook, E.R. Peskind, L.D. Baker, D. Goldgaber, et al. 2005. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch. Neurol. 62:1539-1544. http://dx.doi.org/10.1001/archneur.62.10.noc50112
27. Freude, S., L. Plum, J. Schnitker, U. Leeser, M. Udelhoven, W. Krone, J.C. Bruning, and M. Schubert. 2005. Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes. 54:3343-3348. http://dx.doi.org/10.2337/diabetes.54.12.3343
28. Freude, S., M.M. Hettich, C. Schumann, O. Stöhr, L. Koch, C. Köhler, M. Udelhoven, U. Leeser, M. Müller, N. Kubota, et al. 2009. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FAS EB J. 23:3315-3324. http://dx.doi.org/10.1096/fj.09-132043
29. Frölich, L., D. Blum-Degen, H.G. Bernstein, S. Engelsberger, J. Humrich, S. Laufer, D. Muschner, A. Thalheimer, A. Türk, S. Hoyer, et al. 1998. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna). 105:423-438. http://dx.doi.org/10.1007/s007020050068
30. Fujisawa, Y., K. Sasaki, and K. Akiyama. 1991. Increased insulin levels after OGTT load in peripheral blood and cerebrospinal fluid of patients with dementia of Alzheimer type. Biol. Psychiatry. 30:1219-1228. http://dx.doi.org/10.1016/0006-3223(91)90158-I
31. Gasparini, L., G.K. Gouras, R. Wang, R.S. Gross, M.F. Beal, P. Greengard, and H. Xu. 2001. Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal β-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21:2561-2570.
32. Gil-Bea, F.J., M. Solas, A. Solomon, C. Mugueta, B. Winblad, M. Kivipelto, M.J. Ramirez, and A. Cedazo-Mínguez. 2010. Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J. Alzheimers Dis. 22:405-413.
33. Griffin, R.J., A. Moloney, M. Kelliher, J.A. Johnston, R. Ravid, P. Dockery, R. O'Connor, and C. O'Neill. 2005. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93:105-117. http://dx.doi.org/10.1111/j.1471-4159.2004.02949.x
34. Ho, L., S. Yemul, L. Knable, P. Katsel, R. Zhao, V. Haroutunian, and G.M. Pasinetti. 2012. Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases. Int. J. Alzheimers Dis. 2012:321280. http://dx.doi.org/1155/2012/321280
35. Holtzman, D.M., J.C. Morris, and A.M. Goate. 2011. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3:77sr1. http://dx.doi.org/10.1126/scitranslmed.3002369
36. Hoscheidt, S.M., E.J. Starks, J.M. Oh, H. Zetterberg, K. Blennow, R.A. Krause, C.E. Gleason, L. Puglielli, C.S. Atwood, C.M. Carlsson, et al. 2016. Insulin resistance is associated with increased levels of cerebrospinal fluid biomarkers of Alzheimer's disease and reduced memory function in at-risk healthy middle-aged adults. J. Alzheimers Dis. 12:1373-1383. http://dx.doi.org/10.3233/JAD-160110
37. Janson, J., T. Laedtke, J.E. Parisi, P. O'Brien, R.C. Petersen, and P.C. Butler. 2004. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 53:474-481. http://dx.doi.org/10.2337/diabetes.53.2.474
38. Kapogiannis, D., A. Boxer, J.B. Schwartz, E.L. Abner, A. Biragyn, U. Masharani, L. Frassetto, R.C. Petersen, B.L. Miller, and E.J. Goetzl. 2015. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer's disease. FAS EB J. 29:589-596. http://dx.doi.org/10.1096/fj.14-262048
39. Kuusisto, J., K. Koivisto, L. Mykkänen, E.L. Helkala, M. Vanhanen, T. Hänninen, K. Kervinen, Y.A. Kesäniemi, P.J. Riekkinen, and M. Laakso. 1997. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ. 315:1045-1049. http://dx.doi.org/10.1136/bmj.315.7115.1045
40. Last, D., D.C. Alsop, A.M. Abduljalil, R.P. Marquis, C. de Bazelaire, K. Hu, J. Cavallerano, and V. Novak. 2007. Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care. 30:1193-1199. http://dx.doi.org/10.2337/dc06-2052
41. Liu, Y., F. Liu, I. Grundke-Iqbal, K. Iqbal, and C.X. Gong. 2011. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 225:54-62. http://dx.doi.org/10.1002/path.2912
42. Luchsinger, J.A., M.X. Tang, S. Shea, and R. Mayeux. 2004. Hyperinsulinemia and risk of Alzheimer disease. Neurology. 63:1187-1192. http://dx.doi.org/10.1212/01.WNL.0000140292.04932.87
43. Ma, J., W. Zhang, H.F. Wang, Z.X. Wang, T. Jiang, M.S. Tan, J.T. Yu, and L. Tan. 2016. Peripheral blood adipokines and insulin levels in patients with Alzheimer's disease: a replication study and meta-analysis. Curr. Alzheimer Res. 13:223-233. http://dx.doi.org/10.2174/156720501303160217111434
44. Ma, Q.L., F. Yang, E.R. Rosario, O.J. Ubeda, W. Beech, D.J. Gant, P.P. Chen, B. Hudspeth, C. Chen, Y. Zhao, et al. 2009. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29:9078-9089. http://dx.doi.org/10.1523/JNEUROSCI.1071-09.2009
45. Macauley, S.L., M. Stanley, E.E. Caesar, S.A. Yamada, M.E. Raichle, R. Perez, T.E. Mahan, C.L. Sutphen, and D.M. Holtzman. 2015. Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo. J. Clin. Invest. 125:2463-2467. http://dx.doi.org/10.1172/JCI79742
46. Maioli, S., M. Lodeiro, P. Merino-Serrais, F. Falahati, W. Khan, E. Puerta, A. Codita, R. Rimondini, M.J. Ramirez, A. Simmons, et al. Alzheimer's Disease Neuroimaging Initiative. 2015. Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer's disease. Aging Cell. 14:122-129. http://dx.doi.org/10.1111/acel.12281
47. McNay, E.C., and A.K. Recknagel. 2011. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol. Learn. Mem. 96:432-442. http://dx.doi.org/10.1016/j.nlm.2011.08.005
48. McNay, E.C., C.T. Ong, R.J. McCrimmon, J. Cresswell, J.S. Bogan, and R.S. Sherwin. 2010. Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance. Neurobiol. Learn. Mem. 93:546-553. http://dx.doi.org/10.1016/j.nlm.2010.02.002
49. Molina, J.A., F.J. Jiménez-Jiménez, C. Vargas, P. Gómez, F. de Bustos, C. Gómez-Escalonilla, M. Zurdo, A. Tallón, A. Martínez-Salio, J. Porta-Etessam, et al. 2002. Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. Acta Neurol. Scand. 106:347-350. http://dx.doi.org/10.1034/j.1600-0404.2002.01326.x
50. Moloney, A.M., R.J. Griffin, S. Timmons, R. O'Connor, R. Ravid, and C. O'Neill. 2010. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging. 31:224-243. http://dx.doi.org/10.1016/j.neurobiolaging.2008.04.002
51. Musiek, E.S., and D.M. Holtzman. 2015. Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat. Neurosci. 18:800-806. http://dx.doi.org/10.1038/nn.4018
52. Novak, V., W. Milberg, Y. Hao, M. Munshi, P. Novak, A. Galica, B. Manor, P. Roberson, S. Craft, and A. Abduljalil. 2014. Enhancement of vasoreactivity and cognition by intranasal insulin in type 2 diabetes. Diabetes Care. 37:751-759. http://dx.doi.org/10.2337/dc13-1672
53. Pei, J.J., S. Khatoon, W.L. An, M. Nordlinder, T. Tanaka, H. Braak, I. Tsujio, M. Takeda, I. Alafuzoff, B. Winblad, et al. 2003. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol. 105:381-392.
54. Peila, R., B.L. Rodriguez, L.R. White, and L.J. Launer. 2004. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology. 63:228-233. http://dx.doi.org/10.1212/01.WNL.0000129989.28404.9B
55. Phiel, C.J., C.A. Wilson, V.M. Lee, and P.S. Klein. 2003. GSK-3alpha regulates production of Alzheimer's disease amyloid-βpeptides. Nature. 423:435-439. http://dx.doi.org/10.1038/nature01640
56. Qiu, W.Q., D.M. Walsh, Z. Ye, K. Vekrellis, J. Zhang, M.B. Podlisny, M.R. Rosner, A. Safavi, L.B. Hersh, and D.J. Selkoe. 1998. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273:32730-32738. http://dx.doi.org/10.1074/jbc.273.49.32730
57. Reger, M.A., G.S. Watson, P.S. Green, C.W. Wilkinson, L.D. Baker, B. Cholerton, M.A. Fishel, S.R. Plymate, J.C. Breitner, W. DeGroodt, et al. 2008. Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology. 70:440-448. http://dx.doi.org/10.1212/01.WNL.0000265401.62434.36
58. Rivera, E.J., A. Goldin, N. Fulmer, R. Tavares, J.R. Wands, and S.M. de la Monte. 2005. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 8:247-268.
59. Roberts, R.O., D.S. Knopman, R.H. Cha, M.M. Mielke, V.S. Pankratz, B.F. Boeve, K. Kantarci, Y.E. Geda, C.R. Jack Jr., R.C. Petersen, and V.J. Lowe. 2014. Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J. Nucl. Med. 55:759-764. http://dx.doi.org/10.2967/jnumed.113.132647
60. Sajan, M., B. Hansen, R. Ivey III, J. Sajan, C. Ari, S. Song, U. Braun, M. Leitges, M. Farese-Higgs, and R.V. Farese. 2016. Brain insulin signaling is increased in insulin-resistant states and decreases in FOXOs and PGC-1α and increases in Aβ1-40/42 and phospho-tau may abet Alzheimer development. Diabetes. 65:1892-1903. http://dx.doi.org/10.2337/db15-1428
61. Salameh, T.S., K.M. Bullock, I.A. Hujoel, M.L. Niehoff, T. Wolden-Hanson, J. Kim, J.E. Morley, S.A. Farr, and W.A. Banks. 2015. Central nervous system delivery of intranasal insulin: mechanisms of uptake and effects on cognition. J. Alzheimers Dis. 47:715-728. http://dx.doi.org/10.3233/JAD-150307
62. Sartorius, T., A. Peter, M. Heni, W. Maetzler, A. Fritsche, H.U. Häring, and A.M. Hennige. 2015. The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier? PLoS One. 10:e0126804. http://dx.doi.org/10.1371/journal.pone.0126804
63. Schindowski, K., A. Bretteville, K. Leroy, S. Bégard, J.P. Brion, M. Hamdane, and L. Buée. 2006. Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 169:599-616. http://dx.doi.org/10.2353/ajpath.2006.060002
64. Schubert, M., D. Gautam, D. Surjo, K. Ueki, S. Baudler, D. Schubert, T. Kondo, J. Alber, N. Galldiks, E. Küstermann, et al. 2004. Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA. 101:3100-3105. http://dx.doi.org/10.1073/pnas.0308724101
65. Shiiki, T., S. Ohtsuki, A. Kurihara, H. Naganuma, K. Nishimura, M. Tachikawa, K. Hosoya, and T. Terasaki. 2004. Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J. Neurosci. 24:9632-9637. http://dx.doi.org/10.1523/JNEUROSCI.2236-04.2004
66. Sims-Robinson, C., B. Kim, A. Rosko, and E.L. Feldman. 2010. How does diabetes accelerate Alzheimer disease pathology? Nat. Rev. Neurol. 6:551-559. http://dx.doi.org/10.1038/nrneurol.2010.130
67. Sperling, R.A., P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, A.M. Fagan, T. Iwatsubo, C.R. Jack Jr., J. Kaye, T.J. Montine, et al. 2011. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7:280-292. http://dx.doi.org/10.1016/j.jalz.2011.03.003
68. Starks, E.J., J. Patrick O'Grady, S.M. Hoscheidt, A.M. Racine, C.M. Carlsson, H. Zetterberg, K. Blennow, O.C. Okonkwo, L. Puglielli, S. Asthana, et al. 2015. Insulin resistance is associated with higher cerebrospinal fluid tau levels in asymptomatic APOEe4 carriers. J. Alzheimers Dis. 46:525-533. http://dx.doi.org/10.3233/JAD-150072
69. Steen, E., B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, X.J. Xu, J.R. Wands, and S.M. de la Monte. 2005. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J. Alzheimers Dis. 7:63-80.
70. Stöhr, O., K. Schilbach, L. Moll, M.M. Hettich, S. Freude, F.T. Wunderlich, M. Ernst, J. Zemva, J.C. Brüning, W. Krone, et al. 2013. Insulin receptor signaling mediates APP processing and β-amyloid accumulation without altering survival in a transgenic mouse model of Alzheimer's disease. Age (Dordr.). 35:83-101. http://dx.doi.org/10.1007/s11357-011-9333-2
71. Stolk, R.P., M.M. Breteler, A. Ott, H.A. Pols, S.W. Lamberts, D.E. Grobbee, and A. Hofman. 1997. Insulin and cognitive function in an elderly population. The Rotterdam Study. Diabetes Care. 20:792-795. http://dx.doi.org/10.2337/diacare.20.5.792
72. Talbot, K., H.Y. Wang, H. Kazi, L.Y. Han, K.P. Bakshi, A. Stucky, R.L. Fuino, K.R. Kawaguchi, A.J. Samoyedny, R.S. Wilson, et al. 2012. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122:1316-1338. http://dx.doi.org/10.1172/JCI59903
73. Unger, J., T.H. McNeill, R.T. Moxley III, M. White, A. Moss, and J.N. Livingston. 1989. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 31:143-157. http://dx.doi.org/10.1016/0306-4522(89)90036-5
74. Vandal, M., P.J. White, C. Tremblay, I. St-Amour, G. Chevrier, V. Emond, D. Lefrançois, J. Virgili, E. Planel, Y. Giguere, et al. 2014. Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. Diabetes. 63:4291-4301. http://dx.doi.org/10.2337/db14-0375
75. Wadman, M. 2012. US government sets out Alzheimer's plan. Nature. 485:426-427. http://dx.doi.org/10.1038/485426a
76. Wang, X., W. Zheng, J.W. Xie, T. Wang, S.L. Wang, W.P. Teng, and Z.Y. Wang. 2010. Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol. Neurodegener. 5:46. http://dx.doi.org/10.1186/1750-1326-5-46
77. Watson, G.S., E.R. Peskind, S. Asthana, K. Purganan, C. Wait, D. Chapman, M.W. Schwartz, S. Plymate, and S. Craft. 2003. Insulin increases CSF Aβ42 levels in normal older adults. Neurology. 60:1899-1903. http://dx.doi.org/10.1212/01.WNL.0000065916.25128.25
78. Willette, A.A., S.C. Johnson, A.C. Birdsill, M.A. Sager, B. Christian, L.D. Baker, S. Craft, J. Oh, E. Statz, B.P. Hermann, et al. 2015. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement. 11:504-510.e1. http://dx.doi.org/10.1016/j.jalz.2014.03.011
79. Xie, L., E. Helmerhorst, K. Taddei, B. Plewright, W. Van Bronswijk, and R. Martins. 2002. Alzheimer's β-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 22:RC221.
80. Yarchoan, M., J.B. Toledo, E.B. Lee, Z. Arvanitakis, H. Kazi, L.Y. Han, N. Louneva, V.M. Lee, S.F. Kim, J.Q. Trojanowski, and S.E. Arnold. 2014. Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol. 128:679-689. http://dx.doi.org/10.1007/s00401-014-1328-5
81. Zhang, Y., K. Chen, S.A. Sloan, M.L. Bennett, A.R. Scholze, S. O'Keeffe, H.P. Phatnani, P. Guarnieri, C. Caneda, N. Ruderisch, et al. 2014. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34:11929-11947. http://dx.doi.org/10.1523/JNEUROSCI.1860-14.2014
82. Zhang, Y., C.L. Dai, Y. Chen, K. Iqbal, F. Liu, and C.X. Gong. 2016. Intranasal insulin prevents anesthesia-induced spatial learning and memory deficit in mice. Sci. Rep. 6:21186. http://dx.doi.org/10.1038/srep21186
83. Zhao, W.Q., F.G. De Felice, S. Fernandez, H. Chen, M.P. Lambert, M.J. Quon, G.A. Krafft, and W.L. Klein. 2008. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FAS EB J. 22:246-260. http://dx.doi.org/10.1096/fj.06-7703com
84. Zuchero, Y.J., X. Chen, N. Bien-Ly, D. Bumbaca, R.K. Tong, X. Gao, S. Zhang, K. Hoyte, W. Luk, M.A. Huntley, et al. 2016. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron. 89:70-82. http://dx.doi.org/10.1016/j.neuron.2015.11.024